INSY Insys Therapeutics Inc.

6.16
+0.51  (+9%)
Previous Close 5.65
Open 5.65
Price To Book 2540.24
Market Cap 457501112
Shares 74,269,661
Volume 1,171,729
Short Ratio
Av. Daily Volume 965,916

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due late 1Q 2019.
Cannabidiol
Refractory childhood absence epilepsy
Approved January 5, 2012.
SUBSYS
Cancer pain
Phase 2 initiated August 2016
Pharmaceutical Cannabidiol (CBD)
Cocaine dependence
Announced approval July 5, 2016.
Dronabinol Oral Solution
AIDS-related anorexia
Phase 3 initiation announced March 2, 2018. Noted December 18, 2018 that enrolment has occurred at slower pace than expected.
Pharmaceutical Cannabidiol (CBD)
Infantile spasms (IS)
CRL issued July 27, 2018.
Buprenorphine
Moderate to severe postoperative pain after bunionectomy
NDA filing due 1Q 2019 following data from nonclinical juvenile toxicity trial due March 2019.
Naloxone nasal spray
Opioid overdose
Phase 2 data due 2H 2019.
Cannabidiol
Prader-Willi syndrome